These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 25592212)

  • 1. Big data: not really the same as level 1 data.
    Fasco DR
    Oncology (Williston Park); 2015 Jan; 29(1):70, 72. PubMed ID: 25592212
    [No Abstract]   [Full Text] [Related]  

  • 2. The third analysis of the bicalutamide Early Prostate Cancer programme.
    Iversen P;
    BJU Int; 2006 Mar; 97(3):438-9. PubMed ID: 16469002
    [No Abstract]   [Full Text] [Related]  

  • 3. Apples and oranges. Re: 7.4-year update of the ongoing bicalutamide Early Prostate Cancer (EPC) trial programme.
    Sternberg CN
    BJU Int; 2006 Mar; 97(3):435-8. PubMed ID: 16469001
    [No Abstract]   [Full Text] [Related]  

  • 4. A new method for synthesizing radiation dose-response data from multiple trials applied to prostate cancer: in regard to Diez P, et al. (Int J Radiat Oncol Biol Phys 2010;77:1066-1071).
    Williams SG
    Int J Radiat Oncol Biol Phys; 2011 Jun; 80(2):639; author reply 639-40. PubMed ID: 21549251
    [No Abstract]   [Full Text] [Related]  

  • 5. Development of androgen resistance in prostatic cancer.
    Isaacs JT; Schulze H; Coffey DS
    Prog Clin Biol Res; 1987; 243A():21-31. PubMed ID: 3309971
    [No Abstract]   [Full Text] [Related]  

  • 6. Prostatic adenocarcinoma following androgen deprivation therapy: the new difficulty in histologic interpretation.
    Bostwick DG
    Anat Pathol; 1998; 3():1-16. PubMed ID: 10389579
    [No Abstract]   [Full Text] [Related]  

  • 7. [Total androgen blockade: an argument in favor].
    Labrie F; Lacourcière Y; Bélanger A; Monfette G; Bergeron N; Dupont A; Pinault S; Emond J; Manhès G; Cusan L
    Union Med Can; 1989; 118(1):5. PubMed ID: 2711533
    [No Abstract]   [Full Text] [Related]  

  • 8. Is there a case for total androgen blockade?
    Iversen P
    Prog Clin Biol Res; 1990; 359():109-15; discussion 141-53. PubMed ID: 2284286
    [No Abstract]   [Full Text] [Related]  

  • 9. [How to treat prostatic cancer?].
    Lundberg M
    Lakartidningen; 2005 Aug 8-21; 102(32-33):2244. PubMed ID: 16145890
    [No Abstract]   [Full Text] [Related]  

  • 10. Reasons against total androgen suppression.
    Robinson MR
    Prog Clin Biol Res; 1990; 359():117-24; discussion 141-53. PubMed ID: 2284287
    [No Abstract]   [Full Text] [Related]  

  • 11. [Recent data about prostatic carcinoma (author's transl)].
    Coune A
    Rev Med Brux; 1980 May; 1(5):311-4. PubMed ID: 7466030
    [No Abstract]   [Full Text] [Related]  

  • 12. [Androgenic blockade in metastasizing prostatic carcinoma].
    Tveter KJ
    Tidsskr Nor Laegeforen; 1997 Mar; 117(8):1187. PubMed ID: 9148498
    [No Abstract]   [Full Text] [Related]  

  • 13. Assessment of men before androgen deprivation therapy.
    Maroni P; Crawford ED
    J Urol; 2011 Aug; 186(2):371-2. PubMed ID: 21679987
    [No Abstract]   [Full Text] [Related]  

  • 14. Androgen-deprivation therapy-it's all a matter of timing.
    Anderson J
    Eur Urol; 2008 May; 53(5):869-71. PubMed ID: 18243500
    [No Abstract]   [Full Text] [Related]  

  • 15. The value of reversible androgen suppression as a diagnostic test.
    Newling DW
    Prog Clin Biol Res; 1987; 243A():261-5. PubMed ID: 2958858
    [No Abstract]   [Full Text] [Related]  

  • 16. [Cancer of the prostate: importance of androgen deprivation and radiotherapy].
    Rentsch CA; Aebersold DM; Merz V; Studer UE
    Rev Med Suisse; 2005 May; 1(19):1303-6. PubMed ID: 15962630
    [No Abstract]   [Full Text] [Related]  

  • 17. Intermittent androgen therapy.
    Abi Aad AS; Van Cangh PJ
    Acta Urol Belg; 1996 May; 64(2):91-2. PubMed ID: 8701823
    [No Abstract]   [Full Text] [Related]  

  • 18. [Usefulness and problems of antiandrogen].
    Ozono S; Hirao Y
    Nihon Rinsho; 2000 Jul; 58 Suppl():206-10. PubMed ID: 11022715
    [No Abstract]   [Full Text] [Related]  

  • 19. Androgen deprivation therapy for node-positive prostate cancer: adjuvant does not mean salvage.
    Culine S
    J Clin Oncol; 2009 Jun; 27(17):2888; author reply 2888. PubMed ID: 19398568
    [No Abstract]   [Full Text] [Related]  

  • 20. Endocrine therapy: predictors of response to prostatic cancer.
    Geller J; Albert JD
    Semin Urol; 1983 Nov; 1(4):291-7. PubMed ID: 6399615
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.